Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for FREE ACCESS to this landmark database

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Journal of Child Neurology
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0883073807307108v1
23/4/435    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ondo, W. G.
Right arrow Articles by Davis, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ondo, W. G.
Right arrow Articles by Davis, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Comparison of Weight Gain in Treatments for Tourette Syndrome: Tetrabenazine Versus Neuroleptic Drugs

William G. Ondo, MD

Department of Neurology, Baylor College of Medicine, Houston, Texas, wondo{at}bcm.tmc.edu

Daniel Jong

Department of Neurology, Baylor College of Medicine, Houston, Texas

Anthony Davis, BS

Department of Neurology, Baylor College of Medicine, Houston, Texas

Weight gain occurs with most neuroleptic drugs used to treat tics. Tetrabenazine, a vesicular monoamine transporter type 2 inhibitor, inhibits dopamine release. It is used to treat a variety of hyperkinetic movement disorders, including tics. Weight gain over time was compared in a group of pediatric tic patients taking only tetrabenazine with an age-matched group of tic patients taking only neuroleptic drugs. Age in the tetrabenazine group (n = 36, 32 males) at initial therapy was 13.4 (SD 3.3) years. They were monitored for 25.2 (SD 12.3) months. The average dose of tetrabenazine (all visits) was 54.4 (SD 26.6) mg/d. In the neuroleptic group (n = 41, 33 males), the age at therapy onset was 12.3 ± 4.0 years. They were monitored for 18.9 (SD 14.8) months. Weight increase was 0.8 lb/mo in the tetrabenazine group compared with 1.7 lb/mo in the neuroleptic group (P = .006). Most patients who switched from a neuroleptic drug to tetrabenazine subsequently lost weight. Although the study was not designed to compare efficacy, this tended to be greater with tetrabenazine than with neuroleptic drugs.

Key Words: tics • Tourette syndrome • tetrabenazine • neuroleptics • weight

This version was published on April 1, 2008

Journal of Child Neurology, Vol. 23, No. 4, 435-437 (2008)
DOI: 10.1177/0883073807307108
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?